Menu
Search
|

Menu

Close
X

Atara Biotherapeutics Inc ATRA.OQ (NASDAQ Stock Exchange Global Select Market)

38.86 USD
-- (--)
As of Mar 20
chart
Previous Close 38.86
Open --
Volume --
3m Avg Volume 180,325
Today’s High --
Today’s Low --
52 Week High 54.45
52 Week Low 27.85
Shares Outstanding (mil) 46.16
Market Capitalization (mil) 1,793.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.12 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-5.226
FY17
-3.993
FY16
-2.750
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.82
Price to Sales (TTM)
vs sector
--
9.06
Price to Book (MRQ)
vs sector
5.27
4.61
Price to Cash Flow (TTM)
vs sector
--
40.52
Total Debt to Equity (MRQ)
vs sector
0.00
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
13.95
Return on Investment (TTM)
vs sector
-85.13
12.09
Return on Equity (TTM)
vs sector
-89.29
13.20

EXECUTIVE LEADERSHIP

Isaac Ciechanover
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $562,380.00
Bonus: $320,503.00
Utpal Koppikar
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Joseph Newell
Executive Vice President, Chief Technical Operations Officer, Since 2017
Salary: $258,750.00
Bonus: $191,946.00
Christopher Haqq
Executive Vice President - Research and Development, Chief Scientific Officer, Since 2012
Salary: $416,000.00
Bonus: $154,752.00
Mitchall Clark
Executive Vice President and Chief Regulatory and Quality Assurance Officer, Since 2014
Salary: $231,806.00
Bonus: $90,620.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO   CA   94080-7015

Phone: +1650.2788930

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

SPONSORED STORIES